Understanding VZV Titer Testing: Methods and Clinical Uses

VZV titer testing measures antibodies against varicella-zoster virus, the pathogen behind both chickenpox and shingles, and it serves a surprisingly wide range of clinical purposes. Most commonly ordered to confirm whether someone is immune before starting immunosuppressive therapy, during pregnancy, or as part of healthcare worker screening, the test sounds straightforward but comes with real interpretive quirks. The method your lab uses, whether you were vaccinated or naturally infected, and even unrelated herpes viruses in your system can all influence what the numbers mean.

Why VZV Titers Get Ordered

The most frequent reason you would have a VZV titer drawn is to find out whether you are immune to chickenpox. For most adults who grew up before widespread vaccination, a history of childhood chickenpox is considered reliable evidence of immunity. A study of pregnant women attending prenatal clinics found that among those who reported having had chickenpox, about 98 to 99% tested seropositive, confirming their memory was accurate.¹ But when someone has no clear recollection of having had chickenpox, or says they are unsure, things get murkier. In that same study, only about 7 to 17% of women with a negative or uncertain history actually turned out to be seronegative. That means the majority of people who think they might not be immune actually are, but there is enough uncertainty that a blood test becomes the only way to settle it.

The clinical stakes for getting this right are highest in two groups. The first is people about to start immunosuppressive treatment. Drugs used for inflammatory bowel disease, autoimmune skin conditions, organ transplants, and cancer suppress the immune system in ways that can allow a dormant or new VZV infection to become severe or even life-threatening. Guidelines in dermatology and gastroenterology recommend serological testing before starting these therapies, with vaccination for anyone who tests seronegative.² ³ The window for vaccination closes once the immunosuppressive drugs begin, since the varicella vaccine is a live vaccine and could itself cause disease in an immunocompromised person.

The second major group is healthcare workers. Hospitals need to know whether staff are protected, both for the workers’ own safety and to prevent them from transmitting VZV to vulnerable patients. Serological screening is standard during onboarding, and results guide whether vaccination is needed.

The Gold Standard Nobody Uses Routinely

If you look at the research literature on VZV antibody testing, one method comes up over and over as the benchmark: the fluorescent antibody to membrane antigen test, or FAMA. It has been considered the gold standard for detecting protective VZV antibodies for decades.⁴ The test works by exposing VZV-infected cells to a patient’s serum and then using fluorescent-tagged antibodies to see whether the patient’s antibodies stuck to the viral proteins on the cell surface.

The reason FAMA remains the reference rather than the routine workhorse is practical: it requires live virus-infected cells, trained technicians to read the fluorescence under a microscope, and subjective interpretation of results.⁵ It is labor-intensive and difficult to standardize across labs. So while FAMA is the yardstick that other tests are measured against, it is rarely the test your doctor actually orders.

The Tests You Actually Get

In everyday clinical practice, VZV IgG testing is done by enzyme-linked immunosorbent assay, or ELISA, and its close relatives. These are automated, fast, and available in virtually any commercial laboratory. But not all ELISAs are created equal, and the differences matter more than most clinicians realize.

The main split is between whole-cell ELISAs and glycoprotein-based ELISAs. Whole-cell assays use a broad mixture of proteins from VZV-infected cells as the target antigen. Glycoprotein-based assays use purified viral envelope proteins instead, which are the primary targets of the immune response. A comparison of three commercial ELISAs against the FAMA reference found that two assays (one whole-cell-based and one glycoprotein-based) achieved sensitivities above 99%, while a third assay using purified viral proteins had a lower sensitivity of about 90%.⁶ That study also found that while the ELISAs correlated reasonably well with each other quantitatively, their correlation with FAMA was poor. In other words, two ELISA kits might roughly agree on whether a sample is positive, but neither reliably predicts the exact FAMA titer.

Other studies have produced somewhat different rankings, depending on the specific kits compared and the populations tested. One comparison found that a glycoprotein-based ELISA reached 100% sensitivity for detecting antibodies in people with prior natural infection, while a whole-cell assay managed only 83% in the same group.⁷ But when the same study measured postvaccination immunity, the glycoprotein ELISA’s sensitivity dropped to 87%, and the whole-cell assay fell further to 78%. This hints at a problem that becomes much more significant in the era of vaccination.

A separate Japanese comparison using FAMA as the reference found lower sensitivities for both glycoprotein ELISA and standard enzyme immunoassay, at 67% each, while an older technique called immune adherence hemagglutination (IAHA) lagged behind at 47%.⁸ All three methods showed perfect specificity in that study, meaning they did not falsely label anyone as immune. But their sensitivity gaps mean real immunity gets missed. A related study comparing FAMA, glycoprotein ELISA, standard EIA, and IAHA found that both glycoprotein ELISA and standard EIA agreed with FAMA about 98% of the time among positive samples, while IAHA agreed only 88% of the time.⁹

The practical takeaway from all this is that no single commercial ELISA perfectly matches the gold standard, and performance varies by manufacturer, antigen preparation, and the population being tested. Two different labs using two different kits can give you contradictory results on the same blood sample, and neither is necessarily wrong in a technical sense.

The Vaccination Problem

This is where the evidence gets genuinely messy. People who were vaccinated against chickenpox rather than naturally infected tend to develop lower antibody levels. Most commercially available ELISAs have limited sensitivity for detecting VZV antibodies in vaccinated individuals, who produce lower levels than those with natural infection.¹⁰ This creates a real clinical dilemma: a vaccinated person can test “negative” on a standard commercial ELISA even though they are, in fact, protected.

As the cohort of adults who were vaccinated in childhood grows, this gap becomes a bigger issue. A healthcare worker born after 1995 in the United States likely received the varicella vaccine rather than contracting wild-type chickenpox. If their employer screens them with a commercial ELISA and the result comes back negative or equivocal, does that mean they need another dose of vaccine? Or did the test simply fail to detect their existing immunity? In many cases, the answer is that the test was not sensitive enough, but the standard clinical response is still to re-vaccinate rather than order more specialized (and expensive) testing.

IgM Testing and Acute Diagnosis

While IgG titers measure long-term immunity, IgM antibodies are sometimes ordered to diagnose an active or recent infection. But IgM testing for VZV has serious limitations. IgM does not reliably distinguish a brand-new infection from a reactivation event like shingles, because IgM antibodies can appear in both scenarios. On top of that, VZV-specific IgM tends to be short-lived, making the window for detection narrow and the sensitivity of IgM assays poor.¹¹

A more reliable serological approach to confirming acute infection is to demonstrate IgG seroconversion, meaning a person who tests negative for VZV IgG at symptom onset later tests positive two to three weeks later. For someone who already has detectable IgG, showing at least a fourfold rise in titer over the same period can confirm reactivation or reinfection.¹¹ This paired-serum approach requires patience and two separate blood draws weeks apart, which limits its usefulness for immediate clinical decisions. In practice, when a quick diagnosis is needed, doctors often turn to PCR testing of lesion fluid rather than serology.

Cross-Reactivity With Other Herpes Viruses

VZV belongs to the herpesvirus family, and several of its surface proteins resemble those of herpes simplex virus (HSV). This structural similarity creates a real problem for antibody testing. Crossreactivity between HSV-1 glycoprotein B and VZV glycoprotein II has been documented, meaning a person’s HSV antibodies can sometimes trigger a positive result on a VZV test or vice versa.¹² This is particularly problematic in the diagnosis of central nervous system infections, where clinicians need to determine whether a patient’s neurological symptoms are caused by HSV or VZV. Cross-reactive IgG antibodies are commonly reported in patients with herpes simplex encephalitis, potentially leading to a misdiagnosis of VZV involvement.¹³

Using assays based on VZV glycoprotein E rather than the more broadly reactive glycoproteins can reduce this cross-reactivity, which is why newer research-grade assays target more specific viral proteins. For routine blood screening to check immunity, this cross-reactivity is not usually a major concern, since the clinical question is simply “are antibodies present?” But in neurological settings where the causative agent must be identified correctly, it matters a great deal.

Equivocal Results and What to Do With Them

Commercial VZV IgG assays report results as positive, negative, or equivocal. Equivocal results sit in a gray zone where the measured antibody level is too close to the cutoff for the lab to call it one way or the other. One older study evaluating an automated immunoassay found that all 23 samples repeatedly flagged as equivocal were positive when retested with a latex agglutination assay.¹⁴ This suggests that equivocal results often reflect borderline-positive immunity rather than true susceptibility, but it also highlights how dependent the call is on which assay and which cutoff a laboratory uses.

In practice, many clinicians treat equivocal results as presumptive negatives and recommend vaccination, reasoning that an unnecessary vaccine dose is safer than leaving a potentially susceptible person unprotected. This is a reasonable approach for a healthy adult, but it gets complicated for immunocompromised patients who cannot safely receive the live varicella vaccine. For those patients, retesting with a different method or referring to a reference laboratory may be worth the extra effort.

VZV Antibodies in Cerebrospinal Fluid

One specialized use of VZV titer testing goes beyond simple blood draws. When VZV reactivates and invades the blood vessels of the brain, a condition known as VZV vasculopathy, detection in cerebrospinal fluid (CSF) becomes critical. Interestingly, PCR testing of CSF for viral DNA, which is the go-to method for many other infections, performs poorly here. In one study, all 14 patients with confirmed VZV vasculopathy had anti-VZV IgG detectable in their CSF, but only 28% had VZV DNA.¹⁵ A larger analysis echoed this pattern: 93% of patients had VZV IgG in their CSF while only 30% had detectable viral DNA.¹⁶

The reason antibody testing outperforms DNA testing in this setting is that the virus is primarily damaging blood vessel walls through an inflammatory process, and the viral DNA may have already been cleared by the time the spinal tap is performed. The immune system’s antibody response, by contrast, persists. Confirming that the antibodies were actually produced inside the central nervous system (rather than leaking in from blood) requires comparing the ratio of VZV antibodies in serum versus CSF. A reduced serum-to-CSF ratio confirms local, intrathecal antibody production and clinches the diagnosis.

IgG Avidity Testing

A less commonly ordered but clinically interesting form of VZV serology is the IgG avidity test. Avidity measures how tightly antibodies bind to their target antigen. Early in an immune response, antibodies tend to bind loosely; over time, the immune system refines them into higher-avidity versions. This maturation pattern can help distinguish a recent primary infection from a long-past one, which is useful when timing matters, for example, during pregnancy.¹⁷

Avidity testing has revealed something unexpected about vaccine-induced immunity. Some people who received the varicella vaccine maintain low-avidity antibodies for extended periods, a pattern that differs from what is seen after natural infection and from what other live vaccines produce. This may indicate that the vaccine did not fully engage the T-cell arm of the immune response, resulting in less mature antibodies and potentially less durable protection against reinfection.¹⁸ The clinical implications of this finding are still being studied, but it adds another layer to the question of how well standard titer tests capture true immune protection in vaccinated people.

How Long VZV Antibodies Last

For people with naturally acquired immunity, VZV antibodies are remarkably durable. A large study measuring antibody half-lives to common viruses estimated that VZV antibodies have a half-life of about 50 years, meaning it takes roughly that long for antibody levels to drop by half.¹⁹ This is the shortest half-life among the common viral antibodies measured in that study (measles and mumps antibodies lasted far longer), but it is still long enough that most people who had chickenpox will test positive for life.

Vaccine-induced antibodies tell a different story. A retrospective study of healthcare workers who had been vaccinated (rather than naturally infected) found that an estimated 50% lost detectable anti-varicella IgG after about nine years.²⁰ This does not necessarily mean those individuals lost all protection, since cellular immunity (T cells) plays a major role in VZV defense that antibody tests do not measure. But it does mean that a negative VZV IgG result in a vaccinated person is an increasingly common and increasingly difficult result to interpret.

What Titers Cannot Tell You About Protection

A persistent limitation of all VZV antibody testing is that there is no universally agreed-upon titer level that guarantees protection. Unlike, say, hepatitis B, where a surface antibody level above 10 mIU/mL is widely accepted as protective, VZV immunity lacks a clean numerical cutoff. Part of the reason is that cellular immunity, particularly CD4+ T-cell responses, plays a large role in controlling VZV reactivation and severe disease. The recombinant zoster vaccine (Shingrix), for example, works largely by boosting T-cell responses that persist over time, and immunologic studies have shown higher and more durable T-cell responses with this vaccine compared to the older live zoster vaccine.²¹ A person with a modest antibody titer but strong cellular immunity could be better protected than someone with higher antibodies but weak T-cell responses, and standard titer testing reveals nothing about the T-cell side.

This disconnect is why clinical decisions based on VZV titers are often conservative. A positive result is reassuring. A negative result in someone with a documented vaccine history is ambiguous. And an equivocal result can mean almost anything. Clinicians generally use titer results as one input alongside vaccination records, clinical history, and the specific clinical scenario, rather than treating the number as a definitive verdict on immune status.

Flow Cytometry and Newer Approaches

Research labs have explored alternatives to both the labor-intensive FAMA and the imperfect commercial ELISAs. One approach adapts the FAMA principle to a flow cytometer, which replaces the subjective microscopy reading with a machine-generated fluorescence measurement. An early evaluation of this flow-cytometry FAMA showed about 90% accuracy compared to the standard FAMA test.²² The advantage would be greater objectivity and easier standardization across labs. A virus-free version of FAMA using recombinant VZV glycoproteins expressed on cell surfaces has also been developed, removing the need for handling live virus.⁴ These newer methods are still largely confined to research settings, but they hint at a future where the gap between the gold standard and the everyday test might narrow.